MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston
Texas
77030
United States
Tel: 1-877-731-7527
Website: http://www.mdanderson.org/
195 articles with MD Anderson Cancer Center
-
Steps have been taken to safeguard the cancer center, including development of a cutting-edge approach to Enterprise Risk Management.
-
Moleculin Announces Significant Discovery in Lung Cancer Models
4/17/2019
Annamycin Found to be Active Against Metastatic Lung Cancer in Pre-Clinical Testing
-
Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy
4/17/2019
Study finds that resistant cells become vulnerable to MD Anderson-developed targeted therapy
-
Soliton Completes Cellulite Clinical Trials
4/9/2019
Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announced it has completed the first evaluation timepoint for its proof of concept clinical trial for the treatment of cellulite.
-
The recent CBRE Research report, “2019 U.S. Life Sciences Clusters” has two Texas metropolitan areas in its top-10 fastest-growing life sciences market. Houston ranked third, while Dallas/Ft. Worth ranked seventh. Let’s look at Dallas/Ft. Worth.
-
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
4/4/2019
Dr. Napoleone Ferrara, a Member of DelMar Pharmaceuticals Board Will Serve as the Chairman of the SAB
-
DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083
4/3/2019
DelMar Pharmaceuticals, Inc. announced the University of Texas MD Anderson Cancer Center's Institutional Review Board has approved a trial protocol amendment to expand DelMar's ongoing Phase 2 clinical trial of VAL-083 in patients with MGMT-unmethylated glioblastoma.
-
A recent report by CBRE Research analyzing U.S. life science clusters, found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017. One doesn’t typically think of Texas, let alone Houston, as being a center for the life sciences. Oil, energy and tech, yes, but not...
-
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
-
Single agent umbralisib effective for relapsed slow-growing lymphoma
4/1/2019
MD Anderson Phase II trial shows drug well tolerated with high response rates for marginal zone lymphoma
-
Umbralisib Shows Early Promise for Patients with Marginal Zone Lymphoma
4/1/2019
The investigational therapeutic umbralisib, which targets the molecule PI3K- delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according to early results from the UNITY-NHL phase II clinical trial, which were presented at the AACR Annual Meeting 2019, March 29–April 3.
-
Soliton Initiated Clinical Trials for Treatment of Cellulite in Humans
4/1/2019
Soliton, Inc. summarized its efforts to conduct a proof of concept clinical trial for the treatment of cellulite based on Institutional Review Board approval of the study.
-
New potential therapeutic target for pancreatic cancer discovered
3/27/2019
MD Anderson study demonstrates role of protein syndecan-1 in regulation of KRAS gene
-
ZEB1 throttles therapeutic target, protecting KRAS-mutant lung cancer
3/13/2019
Protein forces a shift in cell type, a plasticity that promotes resistance to targeted therapy
-
Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study
2/28/2019
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy
-
During his two years in office, former Texas Secretary of State Rolando Pablos flexed the muscles of his office to make recruiting biotech and pharma companies a priority.
-
Study finds melanoma brain metastases are immunosuppressive with treatment-resistant metabolism
2/20/2019
Research shows deadly tumors may be vulnerable to drugs that block their energy supply
-
Small cell lung cancer may respond to combination of immunotherapy and DNA damage repair inhibitors
2/18/2019
Preclinical research finds new approach to treating aggressive cancer unresponsive to immunotherapy alone
-
February 15 Research Roundup: Rare Pediatric Cancer, Hibernating Hamsters, Prostate Cancer and More
2/15/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.